A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon 25.000 MMS in subjects after an attack of acute pancreatitis suffering from pancreatic exocrine insufficiency, followed by an open-label long-term extension of nine months.

Trial Profile

A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon 25.000 MMS in subjects after an attack of acute pancreatitis suffering from pancreatic exocrine insufficiency, followed by an open-label long-term extension of nine months.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 Jan 2015

At a glance

  • Drugs Pancreatin (Primary)
  • Indications Exocrine pancreatic insufficiency
  • Focus Therapeutic Use
  • Sponsors Solvay
  • Most Recent Events

    • 22 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top